1. Home
  2. OLP vs ADCT Comparison

OLP vs ADCT Comparison

Compare OLP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo One Liberty Properties Inc.

OLP

One Liberty Properties Inc.

HOLD

Current Price

$21.31

Market Cap

478.2M

Sector

Real Estate

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.88

Market Cap

496.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLP
ADCT
Founded
1982
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
478.2M
496.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OLP
ADCT
Price
$21.31
$3.88
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$7.60
AVG Volume (30 Days)
138.0K
1.7M
Earning Date
11-06-2025
11-10-2025
Dividend Yield
8.38%
N/A
EPS Growth
N/A
N/A
EPS
1.54
N/A
Revenue
$97,423,000.00
$75,209,000.00
Revenue This Year
$7.95
$10.36
Revenue Next Year
$6.06
$3.87
P/E Ratio
$13.96
N/A
Revenue Growth
9.29
6.35
52 Week Low
$19.62
$1.05
52 Week High
$29.23
$4.80

Technical Indicators

Market Signals
Indicator
OLP
ADCT
Relative Strength Index (RSI) 62.54 47.51
Support Level $20.90 $3.15
Resistance Level $21.25 $4.28
Average True Range (ATR) 0.34 0.42
MACD 0.10 -0.00
Stochastic Oscillator 84.39 54.46

Price Performance

Historical Comparison
OLP
ADCT

About OLP One Liberty Properties Inc.

One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: